Somatic Mutations of ERBB2 Kinase Domain in Gastric, Colorectal, and Breast Carcinomas
暂无分享,去创建一个
W. Park | Jung Young Lee | S. Nam | N. Yoo | Kyeongmee Park | S. Y. Kim | C. Park | J. W. Lee | Y. H. Soung | S. H. Kim | S. Lee | Young-Pil Wang | S. Seo | Y. Soung
[1] Sehwan Han,et al. c-myc amplification is associated with HER2 amplification and closely linked with cell proliferation in tissue microarray of nonselected breast cancers. , 2005, Human pathology.
[2] J. Minna,et al. Somatic mutations of the HER2 kinase domain in lung adenocarcinomas. , 2005, Cancer research.
[3] Suk Woo Nam,et al. PIK3CA gene is frequently mutated in breast carcinomas and hepatocellular carcinomas , 2005, Oncogene.
[4] W. Park,et al. Absence of EGFR mutation in the kinase domain in common human cancers besides non‐small cell lung cancer , 2005, International journal of cancer.
[5] Takayuki Kosaka,et al. Mutations of the Epidermal Growth Factor Receptor Gene in Lung Cancer , 2004, Cancer Research.
[6] Andrew D. Yates,et al. Athletics: Momentous sprint at the 2156 Olympics? , 2004, Nature.
[7] R. Wilson,et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. , 2004, Proceedings of the National Academy of Sciences of the United States of America.
[8] S. Gabriel,et al. EGFR Mutations in Lung Cancer: Correlation with Clinical Response to Gefitinib Therapy , 2004, Science.
[9] Patricia L. Harris,et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.
[10] A. Ullrich,et al. The discovery of receptor tyrosine kinases: targets for cancer therapy , 2004, Nature Reviews Cancer.
[11] J. Ptak,et al. High Frequency of Mutations of the PIK3CA Gene in Human Cancers , 2004, Science.
[12] T. Hubbard,et al. A census of human cancer genes , 2004, Nature Reviews Cancer.
[13] Suk Woo Nam,et al. BRAF and KRAS mutations in stomach cancer , 2003, Oncogene.
[14] N. Hynes,et al. The ErbB receptors and their role in cancer progression. , 2003, Experimental cell research.
[15] A. Citri,et al. The deaf and the dumb: the biology of ErbB-2 and ErbB-3. , 2003, Experimental cell research.
[16] Antony W Burgess,et al. Epidermal growth factor receptor: mechanisms of activation and signalling. , 2003, Experimental cell research.
[17] A. Nicholson,et al. Mutations of the BRAF gene in human cancer , 2002, Nature.
[18] Y. Yarden,et al. Biochemical and clinical implications of the ErbB/HER signaling network of growth factor receptors. , 2000, Advances in cancer research.
[19] H. S. Kim,et al. Alterations of the DR5/TRAIL receptor 2 gene in non-small cell lung cancers. , 1999, Cancer research.
[20] N. Robert,et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[21] M. Shin,et al. Alterations of Fas (Apo-1/CD95) gene in non-small cell lung cancer , 1999, Oncogene.
[22] N. Yoo,et al. A simple, precise and economical microdissection technique for analysis of genomic DNA from archival tissue sections , 1998, Virchows Archiv.
[23] S. Rodenhuis,et al. Relationship between K-ras oncogene activation and smoking in adenocarcinoma of the human lung. , 1991, Journal of the National Cancer Institute.
[24] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[25] K. Hagino-Yamagishi,et al. [Oncogene]. , 2019, Gan to kagaku ryoho. Cancer & chemotherapy.